Table 2.
The basic information of the four immune checkpoint inhibitors-related hypophysitis reports.
| Basic parameters analysis | Nivolumab n = 419 | Pembrolizumab n = 149 | Ipilimumab n = 643 | Atezolizumab n = 39‡ |
|---|---|---|---|---|
| Age group | ||||
| Adult | 34 (8.11) | 12 (8.05) | 45 (7.00) | 1 (2.56) |
| Middle aged | 148 (35.32) | 41 (27.52) | 225 (34.99) | 12 (30.77) |
| Aged | 136 (32.46) | 52 (34.90) | 161 (25.04) | 9 (23.08) |
| Aged, 80 and over | 22 (5.25) | 12 (8.05) | 23 (3.58) | NA |
| Missing | 79 (18.85) | 32 (21.48) | 189 (29.39) | 17 (43.59) |
| Gender | ||||
| M | 227 (54.18) | 81 (54.36) | 312 (48.52) | 12 (30.77) |
| F | 149 (35.56) | 54 (36.24) | 189 (29.39) | 8 (20.51) |
| Missing | 43 (10.26) | 14 (9.40) | 142 (22.08) | 19 (48.72) |
| Reporter | ||||
| Physician | 171 (40.81) | 49 (32.89) | 238 (37.01) | 20 (51.28) |
| Pharmacist | 10 (2.39) | 4 (2.68) | 15 (2.33) | 1 (2.56) |
| Other health-professional | 127 (30.31) | 26 (17.45) | 223 (34.68) | 4 (10.26) |
| Consumer | 40 (9.55) | 54 (36.24) | 119 (18.51) | 1 (2.56) |
| Lawyer | 2 (0.48) | NA | NA | NA |
| Missing | 69 (16.47) | 16 (10.74) | 48 (7.47) | 13 (33.33) |
| Outcome* | ||||
| Hospitalization – initial or prolonged | 265 (63.25) | 88 (59.06) | 298 (46.36) | 16 (41.03) |
| Disability | 9 (2.15) | 9 (6.04) | 13 (2.02) | NA |
| Life-threatening | 48 (11.46) | 12 (8.05) | 36 (5.60) | NA |
| Death | 30 (7.16) | 10 (6.71) | 31 (4.82) | 5 (12.82) |
| Other important medical events | 319 (76.13) | 87 (58.39) | 400 (62.21) | 23 (58.97) |
| Country | ||||
| United States of America | 120 (28.64) | 43 (28.86) | 363 (56.45) | 10 (25.64) |
| Japan | 66 (15.75) | 27 (18.12) | 64 (9.95) | 8 (20.51) |
| France, French Republic | 51 (12.17) | 15 (10.07) | 37 (5.75) | 3 (7.69) |
| United Kingdom of Great Britain & Northern Ireland | 9 (2.15) | 3 (2.01) | 15 (2.33) | 1 (2.56) |
| Canada | 5 (1.19) | 1 (0.67) | 3 (0.47) | NA |
| Germany, Federal Republic of | 61 (14.56) | 16 (10.74) | 52 (8.09) | 3 (7.69) |
| Australia, Commonwealth of | 22 (5.25) | 4 (2.68) | 28 (4.35) | NA |
| China, People’s Republic of | 1 (0.24) | 4 (2.68) | NA | 3 (7.69) |
| Other countries | 84 (20.05) | 35 (23.49) | 80 (12.44) | 11 (28.21) |
| Missing | NA | 1 (0.67) | 1 (0.16) | NA |
| Reporting year | ||||
| 2011 | 23 (3.58) | |||
| 2012 | 1 (0.24) | 39 (6.07) | ||
| 2013 | 3 (0.72) | 30 (4.67) | ||
| 2014 | 15 (3.58) | 7 (4.70) | 37 (5.75) | |
| 2015 | 13 (3.10) | 17 (11.41) | 74 (11.51) | 1 (2.56) |
| 2016 | 45 (10.74) | 15 (10.07) | 81 (12.60) | 2 (5.13) |
| 2017 | 75 (17.90) | 19 (12.75) | 75 (11.66) | 5 (12.82) |
| 2018 | 90 (21.48) | 34 (22.82) | 179 (27.84) | 1 (2.56) |
| 2019 | 91 (21.72) | 32 (21.48) | 48 (7.47) | 8 (20.51) |
| 2020 | 59 (14.08) | 15 (10.07) | 28 (4.35) | 8 (20.51) |
| 2021† | 27 (6.44) | 10 (6.71) | 19 (2.95) | 14 (35.90) |
| Indication | ||||
| Malignant melanoma | 155 (36.99) | 25 (16.78) | 342 (53.19) | 4 (10.26) |
| Metastatic malignant melanoma | 65 (15.51) | 29 (19.46) | 154 (23.95) | 2 (5.13) |
| Non-small cell lung cancer | 38 (9.07) | 23 (15.44) | 7 (1.09) | 10 (25.64) |
| Lung adenocarcinoma | 5 (1.19) | 3 (2.01) | NA | 2 (5.13) |
| Renal cell carcinoma | 22 (5.25) | NA | 25 (3.89) | 2 (5.13) |
| Other indications | 112 (26.73) | 55 (36.91) | 73 (11.35) | 18 (46.15) |
| Missing | 22 (5.25) | 14 (9.40) | 42 (6.53) | 1 (2.56) |
*
1 AE may have multiple outcomes.
†
Data for quarters 1 and 2; NA: data not available in the database.
‡
Because there were only 2 cases of atezolizumab-induced lymphocytic hypophysitis, relevant data were not extracted from this study.